← All organizations
Highest phase reached
Phase 3
First clinical trial
Aug 31, 2019Last known activity
Jun 30, 2025
Timeline
2010s
- Jan 1, 2014
Centessa— Founded
2020s
- Feb 17, 2021
Palladio Biosciences— Acquired
Drugs by trial phase (6 distinct, 13 trials)
Phase 3 (1 own, 1 via acquisition)
Phase 2 (1 own, 0 via acquisition)
Indications
Subsidiaries (1 direct, 1 total across the full acquisition tree)
Recent trials (12)
- NCT07082829Lead sponsorPhase 1Jun 30, 2025
- NCT06568302CollaboratorPhase 3Jul 11, 2024
- NCT06568302Lead sponsorPhase 3Jul 11, 2024
- NCT05789537CollaboratorPhase 2Jul 28, 2023
- NCT05789537Lead sponsorPhase 2Jul 28, 2023
- NCT05789524Lead sponsorPhase 2Jul 6, 2023
- NCT05789524CollaboratorPhase 2Jul 6, 2023
- NCT05821777Lead sponsorPhase 1/Phase 2Mar 28, 2023
- NCT05323110CollaboratorPhase 1Apr 14, 2022
- NCT05208866CollaboratorPhase 3Feb 10, 2022
- NCT04443192Lead sponsorPhase 1Aug 3, 2020
- NCT04073498Lead sponsorPhase 1/Phase 2Aug 31, 2019
Details
- Founded
- London, GB Jan 1, 2014
- Last known activity
- Jun 30, 2025
Notes
formerly ApcinteX Ltd